Status:
RECRUITING
Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention
Lead Sponsor:
Federico II University
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Dual Antiplatelet Therapy represents the main therapy for patients presenting with chronic coronary syndromes and undergoing elective PCI. However, most of these patients are not properly covered in t...
Detailed Description
Background and state of the art Dual antiplatelet therapy (DAPT) is the main therapy for patients presenting with chronic coronary syndrome (CCS) undergoing elective percutaneous coronary intervention...
Eligibility Criteria
Inclusion
- Adult patients;
- Signed Informed Consent;
- Chronic coronary syndromes;
- P2Y12-inhibitors naive patients;
- Elective PCI of a functionally significant (FFR ≤ 0.80) de-novo intermediate coronary artery stenoses in a major vessel;
Exclusion
- Underaged patients;
- Acute Conorary Syndromes;
- Already on treatment with P2Y12-inhibitors;
- Heart failure with severe reduction of the left ventricle ejection fraction (LVEF \< 30%);
- Subtotal occlusion (diameter stenosis \> 90%) of the target lesion;
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06089577
Start Date
November 1 2023
End Date
October 1 2026
Last Update
March 13 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Cardiology, University Hospital of Ferrara
Ferrara, Italy, 44124
2
Division of Cardiology - Federico II University Hospital
Naples, Italy, 80131